FEXINIDAZOLE

LOE Approaching

fexinidazole

NDAORALTABLETPriority Review
Approved
Jul 2021
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Clinical Trials
4

Mechanism of Action

Cytochrome P450 1A2 Inhibitors

Pharmacologic Class:

Nitroimidazole Antimicrobial

Clinical Trials (4)

NCT05607173Phase 1Completed

A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

Started Jan 2023
21 enrolled
Hepatic Function Abnormal
NCT03025789Phase 3Completed

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Started Nov 2016
174 enrolled
Trypanosomiasis, AfricanSleeping SicknessTrypanosomiasis; Gambian
NCT01340157Phase 1Completed

Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions

Started Feb 2011
12 enrolled
PK in Healthy Volunteers
NCT00982904Phase 1Completed

Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole

Started Sep 2009
108 enrolled
Human African Trypanosomiasis

Loss of Exclusivity

LOE Date
Jul 16, 2026
4 months away
Exclusivity Expiry
Jul 16, 2028